Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$10.76 ▼ -0.11
(-1.01%)
MKT CAP: $927.4M • VOL: 1.35M
52W L $10 52W H $26
ROARABLE / RQD
E • 27/100
PIOTROSKI
3 / 9
GLUE // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$54.2M | -$81.1M | -$143.3M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$38.6M | -$72.7M | -$135.4M |
| EBITDA (Normalized) | -$50.4M | -$77.9M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$22.8M | $42.0M | -$43.8M |
| Capital Expenditures (CapEx) | $4.7M | $4.0M | — |
| Free Cash Flow (FCF) | -$27.5M | $38.0M | -$43.8M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -41.5% | -45.0% | — |
| Cash & Short-Term Equivalents | $129.9M | $224.3M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $233.1M | $222.9M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR GLUE.